SHARON: Study of Metastatic Cancers in Patients With an Inherited Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives
Summary
The purpose of this phase I trial is to evaluate the safety and efficacy of the combination of melphalan, BCNU, low-dose ethanol, vitamin B12b, and vitamin C, in conjunction with autologous (self) bone marrow stem cell infusion in patients with metastatic pancreatic cancer who have a BRCA1, BRCA2, or PALB2 gene mutation.
General Information
NCT#: NCT04150042
Study ID: GO-1
Trial Phase: Phase I
Trial Sponsor: General Oncology, Inc.
Therapies Used in This Trial: Ascorbic Acid, Ethanol, Melphalan, BCNU, hydroxocobalamin, Autologous bone marrow stem cell infusion